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AbsTrACT
background Dry eye disease (DED) affects more than 
14% of the elderly population causing decrease of 
quality of life, high costs and vision impairment. Current 
treatments for DED aim at lubricating and controlling 
inflammation of the ocular surface. Development of novel 
therapies targeting different pathogenic mechanisms is 
sought-after. The aim of this study is to evaluate safety 
and efficacy of recombinant human nerve growth factor 
(rhNGF) eye drops in patients with DED.
Methods Forty consecutive patients with moderate to 
severe DED were included in a phase IIa, prospective, 
open label, multiple-dose, clinical trial to receive rhNGF 
eye drops at 20 µg/mL (Group 1: G1) or at 4 µg/mL 
(Group 2: G2) concentrations, two times a day in both 
eyes for 28 days (NCT02101281). The primary outcomes 
measures were treatment-emerged adverse events (AE), 
Symptoms Assessment in Dry Eye (SANDE) scale, ocular 
surface staining and Schirmer test.
results Of 40 included patients, 39 completed the trial. 
Both tested rhNGF eye drop concentrations were safe 
and well tolerated. Twenty-nine patients experienced at 
least one AE (14 in G1 and 15 in G2), of which 11 had at 
least 1 related AE (8 in G1 and 3 in G2). Both frequency 
and severity of DED symptoms and ocular surface 
damage showed significant improvement in both groups, 
while tear function improved only in G1.
Conclusions The data of this study indicate that rhNGF 
eye drops in both doses is safe and effective in improving 
symptoms and signs of DED. Randomised clinical trials 
are ongoing to confirm the therapeutic benefit of rhNGF 
in DED.
Trial registration number NCT02101281.
InTroduCTIon
Nerve growth factor (NGF), the first identified and 
most well-known member of the family of neurotro-
phins, plays a crucial role in modulating function of 
central and peripheral nervous systems, endocrine, 
immune and visual system.1 2 Since the discovery 
of NGF in the 1950s, increasing experimental and 
clinical evidence has shown that NGF is an essen-
tial factor for the trophism, sensitivity and healing 
of the cornea and the conjunctiva.3–5 Preliminary 
clinical studies have proven the safety and efficacy 
of topical treatment with murine NGF (mNGF) eye 
drops in patients with neurotrophic keratitis and 
autoimmune corneal ulcers.6–8 Furthermore, data 
from both human and animal studies demonstrate 
that exogenously administered NGF stimulates 
ocular surface wound healing and sensitivity and 
increases tear production and conjunctival goblet 
cells density indicating that NGF may represent a 
potential treatment for dry eye disease (DED).5 9–11
Currently, treatments for dry eye aim at lubri-
cating the exposed epithelia with tear substitutes 
and at controlling ocular surface inflammation 
with immunosuppressive drugs and steroids.12 
Novel therapeutic approaches targeting different 
mechanisms of DED, such as impairment of ocular 
surface sensitivity and epithelial damage, are highly 
required to improve clinical outcomes.
Recently, a novel recombinant human NGF 
(rhNGF) produced in Escherichia coli for the treat-
ment of ocular diseases has been introduced. rhNGF 
eye-drop formulation has been successfully tested in 
a phase I clinical trial showing a good safety and 
tolerability profile.13 In July 2017, European Medi-
cine Agency licensed full market authorisation for 
the use of rhNGF (Cenegermin) eye drops for the 
treatment of moderate and severe neurotrophic 
keratitis, a rare ocular disease characterised by 
impairment of corneal sensitivity, healing and tear 
production (EMA/351805/2017; Committee for 
Medicinal Products for Human Use). Here, we 
present the results of the first clinical trial using 
rhNGF eye drops in patients with moderate to 
severe DED.
MeThods
This was an open-label, single-centre, two-group, 
efficacy and safety study to test two doses of rhNGF 
eye drop solution in patients with DED. The study 
was performed at the Department of Clinical Phar-
macology, Medical University and General Hospital 
of Vienna, Austria. The study was approved by the 
local Ethics Committee (Ethik-Kommission der 
Medizinischen Universität Wien und des Allge-
meines Krankenhauses der Stadt Wien AKH, 
Vienna) and by the Federal Health Authorities. 
The study was performed in accordance with the 
relevant guidelines and the Declaration of Helsinki 
and was carried out according to the general princi-
ples of: ‘ICH Harmonised Tripartite Guidelines for 
Good Clinical Practice’ ( ClinicalTrials. gov Identi-
fier: NCT02101281).
Patients
Following written informed consent, only adult 
patients with a diagnosis of moderate to severe 
DED and no restriction of gender or ethnicity 
 o
n




ol: first published as 10.1136/bjophthalmol-2018-312470 on 3 April 2019. Downloaded from 
2 Sacchetti M, et al. Br J Ophthalmol 2019;0:1–9. doi:10.1136/bjophthalmol-2018-312470
Clinical science
Figure 1 Study design. AE, adverse events; rhNGF, recombinant human nerve growth factor.
were enrolled in this study.14 Inclusion criteria were: (1) lissa-
mine green (LG) staining score greater than three in both cornea 
and conjunctiva (National Eye Institute—NEI—grading system) 
in the worse eye (study eye); (2) Schirmer test type I without 
anaesthesia ≤10 mm/5 min and Tear Film Break-Up Time—
TFBUT—≤10 s. In addition, patients were required to have a 
history of artificial tears' use for dry eye within the 3 months 
prior to study enrolment, and to have an average Visual Analogue 
Scale (VAS) score for typical symptoms of dry eye (foreign body 
sensation, burning/stinging, itching, pain, sticky feeling, blurred 
vision and photophobia)≥25 mm in a 100 mm scale. For each 
treatment group, it was mandatory that at least six patients with 
severe or very severe dry eye (stage 3 or 4 according to the 2007 
Report of the International Dry Eye Workshop—DEWS) were 
included.14
Exclusion criteria were: presence of any ocular disease other 
than dry eye requiring treatment with topical medications; 
use of topical ciclosporin, topical corticosteroids or any other 
topical medication for the treatment of DED; use of therapeutic 
or refractive contact lenses within 30 days from enrolment in 
the study; any active ocular infection or inflammation unrelated 
to DED in either eye; history of ocular surgery in the study eye 
including corneal refractive procedures, within 90 days from 
enrolment in the study; presence or history of any systemic or 
ocular condition that could interfere with the conduct of the 
required study procedures or the interpretation of the study 
results; presence or history of serious adverse reaction or 
significant hypersensitivity to any drug or chemically related 
compounds; significant allergy to drugs, foods, amide, local 
anaesthetics or other materials including commercial artificial 
tears containing hypromellose.
study design
This study was designed to evaluate safety and tolerability of 
rhNGF eye drop administration in patients with dry eye and 
to identify the best dose regimen to be tested in following 
randomised, controlled, masked phase II studies. To achieve 
these objectives, two different cohorts were included: in the first 
cohort, 20 consecutive patients (Group 1 [G1]) received rhNGF 
eye drop solution (Dompé farmaceutici s.p.a., Italy) at a dose 
of 20 µg/mL, 1 drop in each eye (35 µL, corresponding to 0.70 
µg of rhNGF) two times a day for 28 days. After completion of 
all subjects from Group 1, an interim analysis of the on primary 
efficacy and safety variables was performed to identify the dose 
for group 2 (G2). In the protocol, two alternative doses were 
foreseen: the planned dose of rhNGF eye drops solution for 
cohort 2 was either 4 µg/mL or 60 µg/mL concentration two 
times a day for 28 days, depending on the results of cohort 1 
(figure 1).
Before inclusion of the patients, a screening visit was performed 
between day −15 and day −1. After collection of systemic 
and ocular history, a full physical examination, including body 
weight, height and vital signs (blood pressure and pulse rate) was 
performed. Furthermore, ocular examinations were performed 
in the following order: assessment of ocular tolerability (VAS), 
assessment of frequency and severity of DED symptoms, Ocular 
Surface Disease Index (OSDI), best-corrected distance visual 
acuity (ETDRS), slit lamp examination and tear osmolarity. After 
a 10-min break, tear film break-up time (TFBUT) was measured. 
Again separated by a 5-min break, Schirmer test I (without 
anaesthesia) and corneal sensitivity (Cochet-Bonnet) were 
assessed. After another break of 10 min, ocular surface staining 
with LG according to the NEI score was performed. Finally, after 
a 10-min break, applanation tonometry for intraocular pressure 
(IOP) was performed.
In all patients both eyes were treated, whereas only the ‘worse 
eye’ was defined as the study eye and included in the statistical 
analysis.
Patients were evaluated as described above at the screening 
visit (from day −15 to baseline visit at −1 day from treatment 
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Table 1 Demographic and clinical characteristics of patients included in the study
rhnGF 20 µg/mL rhnGF 4 µg/mL P value
Gender—N (%)
  Female 16 (80%) 17 (85%) NSS
  Male 4 (20%) 3 (15%)
Age
  Years (mean±SD) 48.4±12.0 55.9±14.8 NSS
Race
  Caucasian—N (%) 20 (100%) 20 (100%) NSS
Body weight
  kg (mean±SD) 70.7±8.7 73.2±18.3 NSS
Height
  cm (mean±SD) 167.7±8.2 165.1±7.3 NSS
Vital signs
  Blood pressure
   Systolic/Diastolic blood pressure mm Hg (mean±SD) 126.2±15.1/78.5±8.5 123.1±18/75.7±10 NSS
   Pulse rate beats/min (mean±SD) 71.5±7.4 76.1±11 NSS
Dry eye severity (DWES classification-N)
  Mild 0 0 NSS
  Moderate 11 13
  Severe 8 5
  Very severe 1 2
Frequency of DED symptoms (SANDE scale)
  Mean±SD 55.3±27.3 52.8±23.2 NSS
Severity of DED symptoms (SANDE scale)
  Mean±SD 59.7±29.2 60.1±29.6 NSS
OSDI score
  Mean±SD 55.52±21.81 52.48±21.84 NSS
Frequency of AT use
  Number of daily administration (mean±SD) 2.9±3.9 3.3±1.9 NSS
BCVA
  ETDRS number of letters (mean±SD) 85.5±5.5 74.6±21.9 NSS
Ocular surface staining 5.2±2 5.9±2.7 NSS
  (NEI scale) total score cornea (mean±SD) total score 8.1±3.5 6.8±2.7 NSS
  conjunctiva (mean±SD) total score (mean±SD) 13.3±4.9 12.6±5.1 NSS
Cornea sensitivity
  (Cochet-Bonnet esthesiometer) mm (mean±SD) 5.6±0.9 5.4±1.2 NSS
Schirmer test type I
  mm/5 min (mean±SD) 4.1±3.3 5.2±3.7 NSS
Break-up time
  s (mean±SD) 3.4±2 3.0±2.4 NSS
Tear osmolarity (Tear Lab)
  mOsm/L (mean±SD) 313.6±13.7 313.6±16.1 NSS
AT, artificial tears; BCVA, best-corrected visual acuity; DED, dry eye disease; NEI, National Eye Institute; NSS, not statistically significant; OSDI, Ocular Surface Disease Index.
DEWS, Dry Eye Workshop
DEWS, Dry Eye Workshop 
.
initiation), started treatment at day 1 (day one visit) and were 
evaluated at day 8±1 and day 29±1. Patients were also evalu-
ated 4 weeks after the end of treatment (day 56±4).
The use of artificial tears Prosicca Sine monodose solution 
(Agepha Pharmaceuticals GmbH, Austria) was allowed during 
the whole study and the number of daily instillations was 
recorded.
outcome variables
The objective of this study was to assess the efficacy and safety of 
different doses of rhNGF eye drops in patients with DED.
The primary outcomes were clinical efficacy and safety param-
eters including:
 ► Treatment-emerged adverse events (TEAEs), assessed 
throughout the study.
 ► Frequency and severity of DED symptoms evaluated by the 
Symptoms Assessment in Dry Eye (SANDE) scale.
 ► Ocular surface staining evaluated by LG using the NEI 
scales.
 ► Tear production evaluated by Schirmer test type I (without 
anaesthesia).
Secondary outcomes included:
 ► VAS for ocular tolerability evaluating foreign body sensa-
tion, burning/stinging, itching, pain, sticky feeling, blurred 
vision and photophobia.
 ► Tear function evaluated by TFBUT and tear film osmolarity.
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n (%) (n Ae)
rhnGF 4 µg/mL
n=20
n (%) (n Ae)
overall
n=40




n (%) Aes n
subjects
n (%) Aes n
subjects
n (%)PT
All SOCs 36 14 (70%) 65 15 (75%) 101 29 (72.5%)
Eye disorders 32 12 (60%) 46 15 (75%) 78 27 (67.5%)
  Abnormal sensation in eye 4 4 (20%) 9 8 (40%) 13 12 (30%)
  Eye pain 7 5 (25%) 7 6 (30%) 14 11 (27.5%)
  Eye irritation 6 3 (15%) 7 7 (35%) 13 10 (25%)
  Eye pruritus 4 2 (10%) 5 5 (25%) 9 7 (17.5%)
  Vision blurred 4 3 (15%) 2 2 (10%) 6 5 (12.5%)
  Foreign body sensation in eyes 0 0 4 4 (20%) 4 4 (10%)
  Photophobia 2 1 (5%) 3 3 (15%) 5 4 (10%)
  Lacrimation increased 0 0 3 3 (15%) 3 3 (7.5%)
  Visual impairment 1 1 (5%) 1 1 (5%) 2 2 (5%)
  Asthenopia 1 1 (5%) 0 0 1 1 (2.5%)
  Erythema of eyelid 0 0 1 1 (5%) 1 1 (2.5%)
  Eye discharge 1 1 (5%) 0 0 1 1 (2.5%)
  Eye disorder 0 0 1 1 (5%) 1 1 (2.5%)
  Eyelid pain 1 1 (5%) 0 0 1 1 (2.5%)
  Eyelid sensory disorder 0 0 1 1 (5%) 1 1 (2.5%)
  Ocular discomfort 0 0 1 1 (5%) 1 1 (2.5%)
  Ocular hyperaemia 0 0 1 1 (5%) 1 1 (2.5%)
  Vitreous detachment 1 1 (5%) 0 0 1 1 (2.5%)
Infections and infestations 2 2 (10%) 5 5 (25%) 7 7 (17.5%)
  Rhinitis 0 0 2 2 (10%) 2 2 (5%)
  Conjunctivitis bacterial 0 0 1 1 (5%) 1 1 (2.5%)
  Herpes simplex 1 1 (5%) 0 0 1 1 (2.5%)
  Nasopharyngitis 1 1 (5%) 0 0 1 1 (2.5%)
  Sinusitis 0 0 1 1 (5%) 1 1 (2.5%)
  Urinary tract infection 0 0 1 1 (5%) 1 1 (2.5%)
Nervous system disorders 1 1 (5%) 9 5 (25%) 10 6 (15%)
  Headache 0 0 9 5 (25%) 9 5 (12.5%)
  Migraine 1 1 (5%) 0 0 1 1 (2.5%)
Musculoskeletal and connective tissue disorders 0 0 2 2 (10%) 2 2 (5%)
  Back pain 0 0 1 1 (5%) 1 1 (2.5%)
  Neck pain 0 0 1 1 (5%) 1 1 (2.5%)
Ear and labyrinth disorders 1 1 (5%) 0 0 1 1 (2.5%)
  Tinnitus 1 1 (5%) 0 0 1 1 (2.5%)
Gastrointestinal disorders 0 0 1 1 (5%) 1 1 (2.5%)
  Flatulence 0 0 1 1 (5%) 1 1 (2.5%)
Injury, poisoning and procedural complications 0 0 1 1 (5%) 1 1 (2.5%)
  Concussion 0 0 1 1 (5%) 1 1 (2.5%)
  Fall 0 0 1 1 (5%) 1 1 (2.5%)
AE, adverse events; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; SOC, system organ class; TEAEs, treatment-emerged adverse events.
 ► Corneal sensitivity measured by Cochet-Bonnet 
aesthesiometry.
 ► OSDI.
 ► Frequency of artificial tears use.
Safety variables:
 ► IOP.
 ► Best-corrected visual acuity (BCVA).
Methods of assessment of clinical outcomes are available at 
online supplementary file 1.
statistical analysis
As this was an exploratory, phase IIa study, no formal statis-
tical sample size calculation was performed. Considering a 
20%–25% dropout rate, 40 patients (20 per treatment for each 
cohort) were planned to be enrolled in the study. A total of 15 
evaluable patients per group was considered to be appropriate 
for accomplishing the study objective. For each treatment 
group, a minimum of six patients had to have a severe dry eye 
(score 3–4) condition according to 2007 DEWS report. All 40 
patients that were enrolled and received at least one dose of 
study drug were included in the analysis.
Efficacy parameters were evaluated as change from base-
line (screening visit). Efficacy variables of the study eyes were 
compared within each dose group and evaluation visit versus 
baseline values by a two-sided Wilcoxon signed-rank test with 
a nominal α level of 0.05.
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Table 3 Safety and tolerability parameters evaluated during the study period
dose rhnGF eye 
drop (µg/mL)
baseline
(from day −15 







IoP: mm Hg (mean±SD) 20 15.9±1.9 15±1.6* 14.1±1.6* 14.4±1.9* 14.2±2.7*
4 12.7±2.3 12.9±2.4 13.2±2.9 14.1±2.4 13.6±2.5
Frequency of AT use: number of daily administration 
(mean±SD)
20 2.9±3.85 – 1.81±1.9 2.13±2.81 2.87±2.96
4 3.3±1.89 – 1.083±1.54 1.27±1.33 2.46±2.86
bCVA: number of letters ETDRS (mean±SD) 20 85.5±5.5 86.1±5.1 85.9±5.1 86.7±4.4 86.6±3.7
4 74.6±21.9 76.2±20.9 78±19.4* 78.9±15.4* 81.3±13.3*
VAs:
Foreign body sensation mm (mean±SD)
20 48.0±27.8 29.6±26.5* 22.8±25.3* 16.6±24.7* 17.4±25.8*
4 48.3±26.2 47.1±28.6 28.4±27.4* 18.7±19.5* 18.4±25.9*
VAs:
Burning/stinging mm (mean±SD)
20 48.2±23.6 26.9±24.8* 22.4±24.2* 15.5±24.7* 18.0±25.7*
4 46.8±28.6 39.4±28.6 33.1±28.6 21.2±23.4* 16.9±23.6*
VAs: itching mm (mean±SD) 20 43.3±23.5 28.7±26.2* 19.6±18.1* 12.7±21.0* 17.4±26.4*
4 54±26.9 40±30* 29.9±29.9* 19.1±22.4* 18.8±21.9*
VAs: pain mm (mean±SD) 20 40.7±29.5 21.5±24.6* 25.3±34.2* 16.3±28.2* 15.8±27.0*
4 29.5±26.2 27±25 25.4±27.8 16.1±24.9* 12.6±20.3*
VAs:
Sticky feeling mm (mean±SD)
20 30.2±25.6 21.0±22.0* 18.5±21.9* 17.5±28.9* 17.1±30.1*
4 38.8±26.7 37.4±30.9 21.9±27.3* 16.6±26.4* 16.2±23.6*
VAs:
Blurred vision mm (mean±SD)
20 58.7±22.8 34.7±25.6* 28.8±28.5* 17.7±26.5* 19.3±27.6*
4 54.5±31.8 47.5±31.7 37.3±32.5* 25.7±28* 26.1±27.9*
VAs: photophobia mm (mean±SD) 20 59.9±20.8 38.9±30.6* 32.9±30.5* 28.4±31.2* 27.7±32.3*
4 48.1±31.6 53.1±32.5 37.3±31.7 29.8±34.8* 25.1±26.8*
*P<0.05 Wilcoxon signed-rank test.
AT, artificial tears; BCVA, best-corrected visual acuity;IOP, intraocular pressure; VAS, Visual Analogue Scale.
Wilcoxon rank-sum test and Hodges-Lehmann CI were used 
for the comparison between group 1 (20 µg/mL group) and 
group 2 (4 µg/mL group). Changes from baseline of corneal 
and conjunctival LG staining (NEI scale), Schirmer test type 
I and TFBUT were assessed. The statistical analysis was 
performed using SAS V.9.3 TS1M1 software.
The number and percentage of patients with any TEAE 
(coded by System Organ Class and Preferred Term), the 
number of TEAEs, the number and percentage of patients with 
any TEAE by severity (see online supplementary file 2), the 
number and percentage of patients with any TEAE related to 
study drug are presented.
resuLTs
Forty patients with DED were recruited in the study. All 
patients were diagnosed with Non-Sjogren Dry Eye. The first 
group (G1) of 20 consecutive patients (16 females, 4 males, 
mean age 48.4±12.0 years) was treated with rhNGF eye drops 
at 20 µg/mL two times a day for 28 days. Since no safety 
concerns emerged, and the ad interim analysis showed that all 
the three primary efficacy parameters significantly improved, 
the study proceeded with the evaluation of the lower dose of 
rhNGF eye drop solution at 4 µg/mL, two times a day for 
28 days in the second group (G2) of 20 consecutive patients 
with DED (17 females, 3 males, mean age 55.9±14.8 years) 
(figure 1). Thirty-nine patients completed all study visits, and 
only one patient (Group 2) discontinued the treatment due to 
an AE. Statistical analysis was performed for all 40 patients 
since all received at least one dose of the study drug, on a full 
data set basis (table 1).
No changes of vital signs out of the normal range were 
observed throughout the entire study. One patient experienced 
a SAE (commotio cerebri) that did not lead to study drug discon-
tinuation and was considered unrelated to the study drug. A 
total of 29 subjects experienced at least one AE (14 in G1 and 
15 in G2), of which 11 had at least one related AE (eight in 
G1 and 3 in G2). All AEs were classified as mild except one in 
the lower concentration group, that was classified as moderate. 
Among the 101 AEs recorded, 77% were classified as eye disor-
ders (32 AEs in G1 and 46 AEs in G2) (table 2). Altogether, 
the investigator deemed only 15 of the 101 reported TEAEs 
as related to the treatment (abnormal sensation in eye 3 AEs in 
G1; eye pain 2 AEs in G1 and 2 in G2; eye irritation 2 AEs in 
G1 and 1 AE in G2; eye pruritus 1 AE in G1; vision blurred 1 
AE in G1; eye discharge 1 AE in G1; eyelid pain 1 AE in G1; 
eyelid sensory disorder 1 AE in G2)
All the ocular AEs were mild and transient and one patient 
discontinued treatment due to an infection (bacterial conjunc-
tivitis) (table 2).
No safety concerns were observed in both groups of rhNGF 
treatment (table 3). Neither an increase in IOP nor a decrease 
in BCVA was observed. In addition, both higher and lower 
rhNGF eye drop concentrations were well tolerated with 
significant improvement of all symptoms investigated by VAS 
scale.
Both concentrations of rhNGF eye drops induced a signifi-
cant improvement in signs and symptoms of DED at the end of 
treatment period that partially lasted to the end of the follow-up. 
Specifically, a significant improvement in both frequency (G1 
baseline: 55.3±27.3, 4 weeks 28.4±26.2, p<0.0001; G2 base-
line 59.7±29.2, 4 weeks 33.5±26.4, p<0.0001) and severity 
(G1 baseline 52.8±23.2, 4 weeks 25.9±26.9, p=0.0005; G2 
baseline 60.1±29.6, 4 weeks 31.5±25.5; p=0.0002) of DED 
symptoms was observed in both groups (figure 2). In addi-
tion, OSDI scores showed a significant improvement (G1 base-
line 55.5±21.8, 4 weeks 32.6±16.2, p<0.001, G2 baseline: 
52.4±21.8, 4 weeks: 35.7±22.8, p=0.0035) at the end of 
treatment period (figure 2).
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Figure 2 Both high and low doses of rhNGF eye drops treatments showed a significant improvement of DED symptoms evaluated by SANDE and 
OSDI scales (*p<0.05). DED, dry eye disease; rhNGF, recombinant human nerve growth factor; OSDI, Ocular Surface Disease Index; SANDE, Symptoms 
Assessment in Dry Eye.
Both doses of rhNGF eye drops improved ocular surface 
damage at the end of treatment period, as observed by LG 
staining in both group 1 (NEI cornea total score: baseline: 
5.2±2.0, 4 weeks: 1.3±2.2, p<0.001; NEI conjunctiva total 
score baseline: 8.1±3.5, 4 weeks 2.5±1.4, p<0.001) and 
group 2 (NEI cornea total score: baseline: 5.9±2.7, 4 weeks: 
3.0±3.3, p<0.001; conjunctiva total score baseline 6.8±2.7 
vs 4 weeks 4.5±2.1, p<0.001) (figure 3).
These effects were associated with a significant improve-
ment of tear film production and function in G1, but not in 
G2. Specifically, a significant increase of tear film parameters 
was observed in group 1 (Schirmer test I: baseline 4.1±3.3 
mm/5 min, 4 weeks 9.4±7.8 mm/5 min, p=0.0006; TFBUT 
baseline 3.4±2 s vs 4 weeks 6±2.5 s, p=0.0015; tear osmo-
larity baseline: 313.6±13.7 mOsm/L, 4 weeks 308.2±12.3 
mOsm/L, p=0.0427) but not in the group 2 (Schirmer test 
type I: baseline 5.2±3.7 mm/5 min, 4 weeks 8.2±6.8 mm/5 
min, p=0.0734, TFBUT baseline 3±2.4 s, 4 weeks 2.5±1.3 
s, p=0.4087; tear osmolarity: 313.6±16.1 mOsm/L, 4 weeks 
312.5±12.3 mOsm/L; p=0.6144) (figure 4, online supple-
mentary table 1).
A long-lasting effect of rhNGF eye drop treatments was 
observed at the follow-up visit (4 weeks after the end of 
treatment), as compared with baseline values. Specifically, a 
significant improvement of DED symptoms was detected by 
both SANDE (frequency: G1 25.2±26.5, p<0.0001 and G2 
31.7±26.8, p<0.0001; severity: G1 23.9±28.1, p=0.0002 
and G2 31.9±27.9, p=0.0003) and OSDI (G1 32.±21.4, 
p<0.0001; G2 37.7±20.1, p=0.0021) scales. Clinical signs 
of DED were also significantly improved during follow-up as 
shown by ocular surface staining with LG (NEI cornea total 
score G1: 1.2±1.6, p<0.0001 and G2: 3.1±2.9, p<0.0001 
and NEI conjunctival total score G1 4.3±2, p<0.0001; G2 
4.6±2.9, p=0.0004). Similarly, the improvement of tear func-
tion in G1 persisted during follow-up as demonstrated by 
Schirmer I test (8.7±10.2 mm/5 min, p=0.0428) and TFBUT 
(5.6±2.4 s, p=0.0032). Interestingly, the increase in corneal 
sensitivity values reached statistical significance at the final 
visit (G1 baseline: 5.6±0.91 mm, 56 days: 5.88±0.39 mm, 
p=0.0313, G2 baseline: 5.43±1.2 mm, 56 days: 5.93±0.18 
mm, p=0.0391).
Comparison of clinical effects of the two rhNGF doses 
showed a significant improvement of NEI conjunctival total 
score at the end of treatment period (p=0.0012; 95% CI 1.0 
to 5.0) and of TBUT values at both end of treatment period 
(4 weeks, p=0.0019; 95% CI −5.0 to −1) and follow-up (4 
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Figure 3 Both high and low doses of rhNGF eye drops treatments showed a significant improvement of ocular surface damage evaluated by 
lissamine green staining (NEI score) (*p<0.05). NIE, National Eye Institute; rhNGF, recombinant human nerve growth factor.
dIsCussIon
This is the first study that demonstrates the safety and efficacy 
of topically applied rhNGF in patients with DED. Specifically, 
topical ophthalmic formulation of rhNGF at both 4 µg/mL and 
20 µg/mL revealed no local or systemic safety concerns and 
showed good tolerability in patients with moderate to severe 
DED. The majority of AEs were mild in severity and resolved 
without treatment, and no patients were discontinued for AEs 
related to rhNGF eye drop treatment. Our results are in line 
with the safety results observed in the phase II clinical trials 
performed in patients with neurotrophic keratoconjunctivitis 
treated with rhNGF eye drop at concentrations of 20 µg/mL or 
10 µg/mL for 8 weeks. Similar to our study, the results of this 
studies showed a good safety profile of treatment with rhNGF 
eye drop at 20 µg/mL, with eye pain being the most frequent 
treatment-related AE and no new AEs reported as compared 
with other studies.15–17
In this study, 4 weeks treatment with rhNGF eye drops at both 
4 µg/mL and 20 µg/mL was effective in improving ocular surface 
damage and dry eye symptoms. These findings are supported 
by clinical and experimental evidence showing that NGF is 
able to stimulate corneal and conjunctival healing in vitro, in 
animal models of ocular diseases, as well as in patients affected 
by neurotrophic and autoimmune corneal ulcers.5–7 9–11 18 The 
involvement of NGF in patients with dry eye has been previously 
reported, since in this study tear levels of NGF were associ-
ated to the severity of the ocular surface damage.11 19 In fact, 
an increase of NGF levels represents a physiological response 
to tissue damage, in order to stimulate ocular surface epithelial 
healing.5 11 In addition, NGF exerts an antiapoptotic effect on 
human corneal cells, as demonstrated by Chang et al showing 
an upregulation of NGF in corneal epithelial cells under hyper-
osmolar stress, a typical pathogenic mechanism of dry eye.20 
Experimental evidence also showed that topical mNGF admin-
istration in a dog model of dry eye was able to improve ocular 
surface healing and to increase tear production and conjunctival 
goblet cell density.9
In addition, our data indicate that rhNGF treatment at the 
higher concentration significantly increased tear film produc-
tion and function. Specifically, the therapeutic effect on TBUT 
is in line with the in vitro studies showing that NGF induces an 
increase of human goblet cells density and stimulates production 
and release of Mucin-5AC, which regulates tear film stability 
(clinically assessed by TBUT).10 Our results also showed an 
increase of tear production, as demonstrated by the increase of 
Schirmer test values. This finding may be related with the well-
known activity of NGF in increasing ocular surface sensitivity 
and stimulating the tear reflex.3
Our results showed that rhNGF eye drop treatment induced an 
improvement of both signs and symptoms in patients with DED 
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Figure 4 The higher dose of rhNGF at 20 µg/mL concentration showed improvement of lacrimal function at each time point (*p<0.05). rhNGF, 
recombinant human nerve growth factor; TBUT, tear film break-up time.
observed at the first time point (1 week). This rapid effect may 
be related to the well-known mechanisms of action of NGF in 
stimulating epithelial healing and modulating nerve function.5 21
The long-lasting therapeutic effect of rhNGF observed in this 
study is an intriguing observation that is potentially explained 
by its typical neurotrophin-related activities. In fact, NGF exerts 
a well-characterised trophic, tropic and protective action on 
peripheral sensitive nerves, including the ocular surface trigem-
inal supply.1 2 In line with this, experimental and clinical studies 
clearly demonstrated the efficacy of NGF administration in 
restoring ocular surface sensitivity and corneal epithelial integ-
rity in patients with neurotrophic keratopathy, a degenerative 
cornea disease caused by damage of corneal innervation.7 22 We 
can speculate that the long-lasting effect of rhNGF treatment in 
patients with dry eye could also be related to an improvement 
in corneal sensitivity, as demonstrated by Cochet-Bonnet evalu-
ation, representing an additional mechanism in the regulation of 
tear production. Although Cochet-Bonnet esthesiometer assesses 
only mechanical sensitivity and it has some limitations, including 
a low reproducibility, our results suggest that local innervation 
may represent a novel therapeutic target to improve dryness in 
the eye, complained by more than 30% of the elderly popula-
tion, and frequently associated with diabetes and autoimmune 
diseases .23 24 Further studies should be performed to evaluate 
changes of corneal nerves in terms of function and morphology 
during treatment with rhNGF eye drop in patients with DED.
Several limitations have to be considered when interpreting 
our results including the open-label study design, the low sample 
size and the lack of patients with Sjogren’s syndrome dry eye. 
In addition, we cannot exclude that the observed improvement 
of symptoms and signs after rhNGF eye drop treatment may 
be due, at least in part, to a placebo effect.25 The observation 
that rhNGF eye drop treatment at the higher concentration 
was significantly more effective in improving tear film stability 
(TBUT) and conjunctival damage when compared with the 
rhNGF treatment at lower concentration suggests a dose depen-
dent rhNGF therapeutic effect. In conclusion, the results of this 
study demonstrate that topical rhNGF is safe and well tolerated 
in patients with moderate to severe DED. When available, results 
of recently completed randomised, controlled clinical trials on 
larger population of patients with DED will provide additional 
information on the efficacy of topical treatment with rhNGF on 
DED signs and symptoms (NCT03019627, NCT03035864).
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